연구성과로 돌아가기
2023 연구성과별 연구자 정보 (292 / 2675)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| Asynchronous glacial dynamics of LastGlacial Maximum mountain glaciers in the Ikh Bogd Massif,Gobi Altai mountain range, southwestern Mongolia: aspect control on glacier massbalance | Sarikaya, Mehmet Akif | Sarikaya, MA | 5 | Istanbul Tech Univ, Eurasian Inst Earth Sci, TR-34469 Istanbul, Turkiye | ABA-9369-2020 | Sarıkaya, Mehmet | ybseong@korea.ac.kr; | |||
| Asynchronous glacial dynamics of LastGlacial Maximum mountain glaciers in the Ikh Bogd Massif,Gobi Altai mountain range, southwestern Mongolia: aspect control on glacier massbalance | Oh, Jeong-Sik | Oh, JS | 6 | Kyungpook Natl Univ, Dept Geog, Daegu 41566, South Korea | ybseong@korea.ac.kr; | |||||
| Asynchronous glacial dynamics of LastGlacial Maximum mountain glaciers in the Ikh Bogd Massif,Gobi Altai mountain range, southwestern Mongolia: aspect control on glacier massbalance | Sandag, Khadbaatar | Sandag, K | 7 | Mongolian Natl Univ Educ, Dept Geog, Ulaanbaatar 210648, Mongolia | ybseong@korea.ac.kr; | |||||
| Asynchronous glacial dynamics of LastGlacial Maximum mountain glaciers in the Ikh Bogd Massif,Gobi Altai mountain range, southwestern Mongolia: aspect control on glacier massbalance | Yu, Byung Yong | Yu, BY | 8 | Korea Inst Sci & Technol, AMS Lab, Seoul 02792, South Korea | ybseong@korea.ac.kr; | |||||
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Qin, Shukui | Qin, SK | 1 | Nanjing Univ Chinese Med, Jinling Hosp, Nanjing, Peoples R China | pierce.chow@duke-nus.edu.sg; | |||||
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Chen, Minshan | Chen, MS | 2 | Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China | 0000-0001-5241-5425 | Huang, Yi-Hsiang | pierce.chow@duke-nus.edu.sg; | |||
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Cheng, Ann-Lii | Cheng, AL | 3 | Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan | ACM-0936-2022 | Cheng, Ann-Lii | pierce.chow@duke-nus.edu.sg; | |||
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Cheng, Ann-Lii | Cheng, AL | 3 | Natl Taiwan Univ Hosp, Taipei, Taiwan | ACM-0936-2022 | Cheng, Ann-Lii | pierce.chow@duke-nus.edu.sg; | |||
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Kaseb, Ahmed | Kaseb, A | 4 | Univ Texas MD Anderson Canc Ctr, Houston, TX USA | G-4827-2016 | Kose, Fatih | 0000-0002-0156-5973 | Kose, Fatih | pierce.chow@duke-nus.edu.sg; | |
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Kudo, Masatoshi | Kudo, M | 5 | Kindai Univ, Osaka, Japan | AAA-9744-2019 | Kudo, Masatoshi | pierce.chow@duke-nus.edu.sg; | |||
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Lee, Han Chu | Lee, HC | 6 | Univ Ulsan, Coll Med, Asan Med Ctr,Dept Gastroenterol, Seoul, South Korea | pierce.chow@duke-nus.edu.sg; | |||||
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Yopp, Adam C. | Yopp, AC | 7 | Univ Texas Southwestern Med Ctr, Dept Surg, Div Surg Oncol, Dallas, TX USA | pierce.chow@duke-nus.edu.sg; | |||||
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Zhou, Jian | Zhou, J | 8 | Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China | pierce.chow@duke-nus.edu.sg; | |||||
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Wang, Lu | Wang, L | 9 | Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China | pierce.chow@duke-nus.edu.sg; | |||||
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Wen, Xiaoyu | Wen, XY | 10 | 1st Hosp Jilin Univ, Jilin, Peoples R China | pierce.chow@duke-nus.edu.sg; |
페이지 이동: